Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2011
Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma
Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Guideline
- Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma.Bone marrow transplantation · 2021Trial
- Paired dosimetric comparison of VMAT-based total body and total marrow irradiation in adult leukemia patients: enhanced organ sparing with consistent plan complexity.Frontiers in oncology · 2026Article
- Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies.Frontiers in medicine · 2023Review
- Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy.Frontiers in oncology · 2022Article
- Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review.Frontiers in oncology · 2022Review
- Safety and efficacy of a nonmyeloablative pretransplant conditioning regimen using total lymphoid irradiation with volumetric modulated arc therapy in healthy dogs: A pilot study.Veterinary medicine and science · 2021Article
- Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?Current oncology (Toronto, Ont.) · 2021Article
- Leaf open time sinogram (LOTS): a novel approach for patient specific quality assurance of total marrow irradiation.Radiation oncology (London, England) · 2020Article
- Local Recurrence Following Total Marrow Radiation: Implications for Clinical Target Delineation.Cureus · 2020Article
- Total marrow and lymphoid irradiation with helical tomotherapy: a practical implementation report.Radiation oncology journal · 2020Article
- Organ sparing of linac-based targeted marrow irradiation over total body irradiation.Journal of applied clinical medical physics · 2019Article
- Fast Megavoltage Computed Tomography: A Rapid Imaging Method for Total Body or Marrow Irradiation in Helical Tomotherapy.International journal of radiation oncology, biology, physics · 2016Article
- Deficiency of lipid phosphatase SHIP enables long-term reconstitution of hematopoietic inductive bone marrow microenvironment.Developmental cell · 2013Article
- Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.International journal of radiation oncology, biology, physics · 2013Article
- Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma.BioMed research international · 2013Article
- Article
- Accelerated large volume irradiation with dynamic Jaw/Dynamic Couch Helical Tomotherapy.Radiation oncology (London, England) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeTo establish feasibility, maximum tolerated dose (MTD), and potential efficacy of ablative dose total marrow irradiation (TMI) delivered by helical tomotherapy in patients with multiple myeloma (MM). EXPERIMENTAL
designPatients with responding or stable MM received tandem autologous stem cell transplants, first with melphalan 200 mg/m(2), and 60 days or later with TMI. TMI doses were to be escalated from 1,000 cGy by increments of 200 cGy. All patients received thalidomide and dexamethasone maintenance.
resultsTwenty-two of 25 enrolled patients (79%) received tandem autologous stem cell transplantation (TASCT): TMI was administered at a median of 63.5 days (44-119) after melphalan. Dose-limiting toxicities at level 5 (1,800 cGy) included reversible grade 3 pneumonitis, congestive heart failure, and enteritis (1), and grade 3 hypotension (1). The estimated median radiation dose to normal organs was 11% to 81% of the prescribed marrow dose. Late toxicities included reversible enteritis (1), and lower extremity deep venous thrombosis during maintenance therapy (2). The complete and very good partial response rates were 55% and 27% following TASCT and maintenance therapy. At a median of 35 months of follow-up (21-50+ months), progression-free and overall survival for all patients were 49% (95% CI, 0.27-0.71) and 82% (0.67-1.00).
conclusionAblative dose TMI as part of TASCT is feasible, and the complete response rate is encouraging. Careful monitoring of late toxicities is needed. Further assessment of this modality is justified at the 1,600 cGy MTD level in MM patients who are candidates for ASCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.